Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.

This article was originally published in The Gray Sheet

Executive Summary

OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26
Advertisement

Related Content

OraSure Taps Former J&J Exec For CEO Post; OraQuick Obtains CLIA Waiver
OraSure Taps Former J&J Exec For CEO Post; OraQuick Obtains CLIA Waiver
OraSure HIV test nears market entry
OraSure HIV test nears market entry
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
Advertisement
UsernamePublicRestriction

Register

MT019982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel